BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 26728853)

  • 1. Defective control of pre-messenger RNA splicing in human disease.
    Chabot B; Shkreta L
    J Cell Biol; 2016 Jan; 212(1):13-27. PubMed ID: 26728853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.
    Boultwood J; Dolatshad H; Varanasi SS; Yip BH; Pellagatti A
    Adv Biol Regul; 2014 Jan; 54():153-61. PubMed ID: 24080589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Brief: (mis)splicing in disease.
    Pedrotti S; Cooper TA
    J Pathol; 2014 May; 233(1):1-3. PubMed ID: 24615176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Splicing Factor Mutations in Cancer.
    Bejar R
    Adv Exp Med Biol; 2016; 907():215-28. PubMed ID: 27256388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spliceosomal factor mutations and mis-splicing in MDS.
    Hershberger CE; Daniels NJ; Padgett RA
    Best Pract Res Clin Haematol; 2020 Sep; 33(3):101199. PubMed ID: 33038983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Deregulation of pre-messenger RNA splicing and rare diseases].
    de la Grange P
    Med Sci (Paris); 2016 Dec; 32(12):1111-1119. PubMed ID: 28044975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Charting the "Splice" Routes to MDS.
    Obeng EA; Ebert BL
    Cancer Cell; 2015 May; 27(5):607-9. PubMed ID: 25965565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo.
    Shirai CL; Ley JN; White BS; Kim S; Tibbitts J; Shao J; Ndonwi M; Wadugu B; Duncavage EJ; Okeyo-Owuor T; Liu T; Griffith M; McGrath S; Magrini V; Fulton RS; Fronick C; O'Laughlin M; Graubert TA; Walter MJ
    Cancer Cell; 2015 May; 27(5):631-43. PubMed ID: 25965570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Point mutations of genes encoding proteins involvedin RNA splicing in patients with myelodysplastic syndromes].
    Barańska M; Czerwińska-Rybak J; Gil L; Komarnicki M
    Pol Merkur Lekarski; 2015 Jan; 38(223):5-10. PubMed ID: 25763580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells.
    Liang Y; Tebaldi T; Rejeski K; Joshi P; Stefani G; Taylor A; Song Y; Vasic R; Maziarz J; Balasubramanian K; Ardasheva A; Ding A; Quattrone A; Halene S
    Leukemia; 2018 Dec; 32(12):2659-2671. PubMed ID: 29858584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes.
    Yip BH; Dolatshad H; Roy S; Pellagatti A; Boultwood J
    Curr Pharm Des; 2016; 22(16):2333-44. PubMed ID: 26916023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors.
    Scott LM; Rebel VI
    J Natl Cancer Inst; 2013 Oct; 105(20):1540-9. PubMed ID: 24052622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
    Brierley CK; Steensma DP
    Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-mRNA Splicing in Plants: In Vivo Functions of RNA-Binding Proteins Implicated in the Splicing Process.
    Meyer K; Koester T; Staiger D
    Biomolecules; 2015 Jul; 5(3):1717-40. PubMed ID: 26213982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing.
    Zhao J; Sun Y; Huang Y; Song F; Huang Z; Bao Y; Zuo J; Saffen D; Shao Z; Liu W; Wang Y
    Sci Rep; 2017 Jan; 7():40488. PubMed ID: 28091594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing.
    Shkreta L; Bell B; Revil T; Venables JP; Prinos P; Elela SA; Chabot B
    Cancer Treat Res; 2013; 158():41-94. PubMed ID: 24222354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How do messenger RNA splicing alterations drive myelodysplasia?
    Joshi P; Halene S; Abdel-Wahab O
    Blood; 2017 May; 129(18):2465-2470. PubMed ID: 28348147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A neuron-specific splicing switch mediated by an array of pre-mRNA repressor sites: evidence of a regulatory role for the polypyrimidine tract binding protein and a brain-specific PTB counterpart.
    Ashiya M; Grabowski PJ
    RNA; 1997 Sep; 3(9):996-1015. PubMed ID: 9292499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant RNA splicing and therapeutic opportunities in cancers.
    Yamauchi H; Nishimura K; Yoshimi A
    Cancer Sci; 2022 Feb; 113(2):373-381. PubMed ID: 34812550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The SR protein family: pleiotropic functions in pre-mRNA splicing.
    Valcárcel J; Green MR
    Trends Biochem Sci; 1996 Aug; 21(8):296-301. PubMed ID: 8772383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.